Leuppi Jörg D, Bridevaux Pierre-Olivier, Charbonnier Florian, Clarenbach Christian, Duchna Hans-Werner, Gianella Pietro, Jochmann Anja, Kern Lukas, Meyer Franca, Pavlov Nikolay, Rothe Thomas, Steurer-Stey Claudia, Von Garnier Christophe
Clinique universitaire de médecine, Hôpital Cantonal de Bâle-Campagne, 4410 Liestal.
Faculté de médecine, Université de Bâle, 4001 Bâle.
Rev Med Suisse. 2022 Jun 22;18(787):1269-1274. doi: 10.53738/REVMED.2022.18.787.1269.
For general practitioners there have been important novelties in the treatment of asthma due to recent modifications of the international guidelines from Global Initiative for Asthma (GINA). In Step 1, use of short-acting beta2-agonists (SABA) without concomitant inhaled corticosteroids (ICS) as controller is no longer recommended for lack of efficacy and safety reasons. Instead, low dose ICS-formoterol as needed is recommended. In Step 5, in patients with severe uncontrolled asthma GINA recommends targeted biologic therapies like interleukin antibodies. Asthma patients presenting simultaneously with symptoms of chronic obstructive pulmonary disease (COPD) should receive treatment containing ICS. Independent of the current corona pandemic, GINA recommendations stay in place.
对于全科医生而言，由于全球哮喘防治创议（GINA）近期对国际指南进行了修订，哮喘治疗出现了一些重要的新变化。在第1步中，由于缺乏有效性和安全性，不再推荐使用短效β2激动剂（SABA）而不联合吸入性糖皮质激素（ICS）作为控制药物。相反，推荐按需使用低剂量ICS-福莫特罗。在第5步中，对于重度未控制哮喘患者，GINA推荐使用如白细胞介素抗体等靶向生物疗法。同时出现慢性阻塞性肺疾病（COPD）症状的哮喘患者应接受含ICS的治疗。无论当前的新冠疫情如何，GINA的建议仍然适用。
